^
    Back
    Association details:
    Biomarker:POLE A456P
    Cancer:Colon Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Clinicopathological and genomic characteristics of POLE-mutated colorectal cancer in a Chinese population

    Published date:
    05/19/2021
    Excerpt:
    A MSS patient with metastatic colon cancer harboring A456P POLE mutation responsed well to the immunotherpy and achieved a partial response.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e15531